Hepatic drug delivery and gene therapy

Mark A Zern, Thomas F. Kresina

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

On September 21-22, 1995, an international meeting entitled 'Targeting of Novel Therapeutics to the Liver and GI Tract' was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the 'state of the art' for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as pesters at the conference.

Original languageEnglish (US)
Pages (from-to)484-491
Number of pages8
JournalHepatology
Volume25
Issue number2
StatePublished - Feb 1997
Externally publishedYes

Fingerprint

Genetic Therapy
Drug Therapy
Liver
Liver Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Metabolic Diseases
National Institutes of Health (U.S.)
Hepatitis
HIV Infections
Gastrointestinal Tract
Technology
Health
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hepatology

Cite this

Zern, M. A., & Kresina, T. F. (1997). Hepatic drug delivery and gene therapy. Hepatology, 25(2), 484-491.

Hepatic drug delivery and gene therapy. / Zern, Mark A; Kresina, Thomas F.

In: Hepatology, Vol. 25, No. 2, 02.1997, p. 484-491.

Research output: Contribution to journalArticle

Zern, MA & Kresina, TF 1997, 'Hepatic drug delivery and gene therapy', Hepatology, vol. 25, no. 2, pp. 484-491.
Zern MA, Kresina TF. Hepatic drug delivery and gene therapy. Hepatology. 1997 Feb;25(2):484-491.
Zern, Mark A ; Kresina, Thomas F. / Hepatic drug delivery and gene therapy. In: Hepatology. 1997 ; Vol. 25, No. 2. pp. 484-491.
@article{51c71757882447d281e279c9f27b5059,
title = "Hepatic drug delivery and gene therapy",
abstract = "On September 21-22, 1995, an international meeting entitled 'Targeting of Novel Therapeutics to the Liver and GI Tract' was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the 'state of the art' for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as pesters at the conference.",
author = "Zern, {Mark A} and Kresina, {Thomas F.}",
year = "1997",
month = "2",
language = "English (US)",
volume = "25",
pages = "484--491",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Hepatic drug delivery and gene therapy

AU - Zern, Mark A

AU - Kresina, Thomas F.

PY - 1997/2

Y1 - 1997/2

N2 - On September 21-22, 1995, an international meeting entitled 'Targeting of Novel Therapeutics to the Liver and GI Tract' was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the 'state of the art' for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as pesters at the conference.

AB - On September 21-22, 1995, an international meeting entitled 'Targeting of Novel Therapeutics to the Liver and GI Tract' was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the 'state of the art' for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as pesters at the conference.

UR - http://www.scopus.com/inward/record.url?scp=0031014778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031014778&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 484

EP - 491

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -